Sarepta Therapeutics (NASDAQ: SRPT) stock rose over 3% Thursday after Pfizer (NYSE: PFE) announced disappointing results from its Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE